Xylometazoline Induced Isolated Left Medial Cerebellar Peduncle Infarct: A Rare Case Report

ABSTRACT

Xylometazoline, a sympathomimetic available as over the counter drug, acts as a nasal decongestant and has been reported as an independent risk factor for hemorrhagic and ischemic stroke. The chronic use of xylometazoline leads to either increased release of more potent vasoconstrictor norepinephrine in the presynaptic region, or acts directly on central adrenoreceptors which leads to dysfunction resulting in chronic progressive vasculopathy that manifests as an ischemic stroke. Sympathomimetics also activate 12-lipoxygenase pathways which induce proliferation and migration of vascular smooth muscle cells. 12-lipoxgenase also plays a significant role in regulating the degree and stability of platelet activation, as its activation significantly strengthens platelet activation and uncontrolled platelet activation, which may lead to myocardial infraction and stroke. The present case reports a rare case of young adult suffering from isolated left medial cerebellar peduncle infarct related to the chronic use of xylometazoline. Acute cerebellar stroke is rare, especially in young adults and represent only 3% of total ischemic and hemorrhagic strokes. Clinical symptoms, patient age at the onset of stroke, and lesion size had no significant effect on the clinical outcome. Symptoms are frequently underestimated and misdiagnosed which further lead to serious complications and poor functional outcomes.

KEYWORDS

• Xylometazoline
• Sympathomimetics
• Nasal decongestants
• Cerebellar infarct

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.1177/0976500X221080224Copy

RELATED ARTICLES

Matched on section and article type within this issue of J Pharmacol. Pharmacother..

• Article · VOLUME 13, ISSUE 1Bullous Drug Reaction with Dipeptidyl Peptidase-4 (DPP-4) InhibitorsK. Geetha, Puja Puja · pp. 99–101Case ReportSame type: Article
• Article · VOLUME 13, ISSUE 1Systematic Review and Meta-Analysis Comparing the Safety of Natalizumab, Ocrelizumab, and Alemtuzumab in Treating Relapsing–Remitting, Primary Progressive, and Secondary Progressive Multiple SclerosisPooja Raina, Somnath Basu, Ramesh K Goyal, Pravat K Sahoo, Rajani Mathur · pp. 14–23Same type: Article
• Article · VOLUME 13, ISSUE 1Review of the Long-Term Effect of the Atypical Antipsychotic Medication on the Bone Mineral Density of the Pediatric Patient with Consideration of Autism Spectrum DisorderWisam Al Jumaili, Ashraf Muzwagi · pp. 24–30Same type: Article
• Article · VOLUME 13, ISSUE 1The Role of Olfactory System in the Etiogenesis of Parkinson’s Diseases: An OverviewJiju Narayanan Avanipully, Dithu Thekkekkara, Sahyadri M, Vipan K. Parihar, Santhepete Nanjundaiah Manjula · pp. 31–39Same type: Article